Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer - Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA, Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI. J Natl Cancer Inst 2003;95:661-668

Author： Chatta G.  

Publisher： Elsevier

ISSN： 1078-1439

Source： Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.6, 2003-11, pp. : 488-488

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message? - Chan EC, Vernon SW, O'Donnell FT, Ahn C, Greisinger A, Aga DW, Division of General Internal Medicine, University of Texas-Houston Medical School, Houston, TX. Am J Public Health 2003;93:779-785

By Carroll P.R.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 484-484

Elsevier

Access to resources Recommend Favorite

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy - D'Aimco AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M-H, Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA. J Natl Cancer Inst 2003;95:1376-1383

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 487-488

Elsevier

Access to resources Recommend Favorite

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL, Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA - Proc Natl Acad Sci USA 2003;100:1250-1255

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 411-412

Elsevier

Access to resources Recommend Favorite

Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the department of defense (DOD) Center for Prostate Disease Research (CPDR) national database

By Moul J.W.   Sun L.   Wu H.   McLeod D.G.   Amling C.   Lance R.   Foley J.   Sexton W.   Kusuda L.   Chung A.   Soderdahl D.   Donahue T.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 447-455

Elsevier

Access to resources Recommend Favorite

Prostate-specific antigen

By Stenman U-H.   Leinonen J.   Zhang W-M.   Finne P.  

Seminars in Cancer Biology, Vol. 9, Iss. 2, 1999-04 ,pp. : 83-93

Academic Press

Access to resources Recommend Favorite